Robert J. Noecker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert J. Noecker has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Larissa Camejo
2 shared publicationsThomas Mundorf
Private Practice, Charlotte, NC, USA
2 shared publicationsDiane T W Chang
Department of Ophthalmology, University of Pittsburgh Medical Center, Eye Center, Pittsburgh, PA, USA
1 shared publicationJanet Serle
Mount Sinai School of Medicine, New York City, USA
1 shared publicationJay Katz
1 shared publicationJoel S Schuman
1 shared publication
Latest Publications
- 1 July 2011
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 37 (7) , 1355-1359
Recurrent enterococcal endophthalmitis seeded by an intraocular lens biofilm
A case of endophthalmitis following uneventful phacoemulsification and posterior chamber intraocular lens (IOL) implantation in a 77-year-old diabetic man was culture-positive for Enterococcus faecalis. After successful treatment with intravitreal, topical, and systemic antibiotic agents, the infection seemed to clear and the patient achieved a corrected visual acuity of 20/25. Four months after the initial presentation, the patient again developed signs and symptoms of endophthalmitis, with regrowth of E faecalis. The antibiotic therapy was repeated. One month later, the IOL was removed surgically and found to harbor a biofilm of the strain demonstrated by DNA analysis. The microbiologic and DNA analyses support that a biofilm on an IOL could be a vector for a cause of recurrent endophthalmitis. Intraocular lens exchange in cases of postoperative endophthalmitis caused by E faecalis may be considered to decrease the risk for recurrent infection.
- 1 July 2011
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 37 (7) , 1355-1359
Recurrent enterococcal endophthalmitis seeded by an intraocular lens biofilm
A case of endophthalmitis following uneventful phacoemulsification and posterior chamber intraocular lens (IOL) implantation in a 77-year-old diabetic man was culture-positive for Enterococcus faecalis. After successful treatment with intravitreal, topical, and systemic antibiotic agents, the infection seemed to clear and the patient achieved a corrected visual acuity of 20/25. Four months after the initial presentation, the patient again developed signs and symptoms of endophthalmitis, with regrowth of E faecalis. The antibiotic therapy was repeated. One month later, the IOL was removed surgically and found to harbor a biofilm of the strain demonstrated by DNA analysis. The microbiologic and DNA analyses support that a biofilm on an IOL could be a vector for a cause of recurrent endophthalmitis. Intraocular lens exchange in cases of postoperative endophthalmitis caused by E faecalis may be considered to decrease the risk for recurrent infection.
- Open Access
- 1 May 2009
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 3, 345-55
Intracameral dexamethasone reduces inflammation on the first postoperative day after cataract surgery in eyes with and without glaucoma
Peer reviewed article authored by (Diane TW Chang, Michael C Herceg, Richard A Bilonick, Larissa Camejo, et al.). Read article or submit your manuscript for publishing.
- 1 May 2009
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 3, 345-55
Open AccessIntracameral dexamethasone reduces inflammation on the first postoperative day after cataract surgery in eyes with and without glaucoma
Peer reviewed article authored by (Diane TW Chang, Michael C Herceg, Richard A Bilonick, Larissa Camejo, et al.). Read article or submit your manuscript for publishing.
- Open Access
- 1 August 2008
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 2 (4) , 769-72
Effect of audible and visual reminders on adherence in glaucoma patients using a commercially available dosing aid
Peer reviewed article authored by (Lawrence Y Ho, Larissa Camejo, Malik Y Kahook, Robert Noecker). Read article or submit your manuscript for publishing.
- 1 August 2008
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 2 (4) , 769-72
Open AccessEffect of audible and visual reminders on adherence in glaucoma patients using a commercially available dosing aid
Peer reviewed article authored by (Lawrence Y Ho, Larissa Camejo, Malik Y Kahook, Robert Noecker). Read article or submit your manuscript for publishing.
- 31 July 2008
- Published by Springer Nature in Advances in Therapy
- Vol. 25 (8) , 743-751
Quantitative analysis of conjunctival goblet cells after chronic application of topical drops
Chronic topical glaucoma therapy has been reported to cause deleterious changes to the ocular surface epithelial layers. We compare changes in the number of goblet cells after chronic exposure to latanoprost preserved with 0.02% benzalkonium chloride (BAK) eye drops (Xalatan®; Pfizer, NY, USA), travoprost preserved with sofZia® eye drops (Travatan Z®; Alcon, Fort Worth, TX, USA), or preservative-free artificial tears (Refresh Plus®; Allergan, Irvine, CA, USA). Fifteen New Zealand white rabbits were randomised into groups of five (one eye was randomised for treatment) and received once-daily topical application of one of the three treatments for 30 days. Enucleation was performed at the end of the study followed by histologic analysis using mucin stains to identify goblet cells. Goblet cells were quantified and analysed using Student t tests to compare means between groups. Goblet cells per high-power field were 2.21 (±0.40) in the latanoprost with BAK group, 6.02 (±1.20) in the travoprost with sofZia group, and 7.03 (±1.33) in the preservative-free artificial tear group. The number of goblet cells in the latanoprost with BAK group was significantly lower than the other two groups (P=0.0001). There was no statistically significant difference in goblet cell numbers between the travoprost with sofZia and preservative-free artificial tear group (P=0.24). Our study illustrates that, in this animal model, once-daily dosing of latanoprost with 0.02% BAK resulted in goblet cell loss compared with dosing with either travoprost with sofZia or preservative-free artificial tears.
- 31 July 2008
- Published by Springer Nature in Advances in Therapy
- Vol. 25 (8) , 743-751
Quantitative analysis of conjunctival goblet cells after chronic application of topical drops
Chronic topical glaucoma therapy has been reported to cause deleterious changes to the ocular surface epithelial layers. We compare changes in the number of goblet cells after chronic exposure to latanoprost preserved with 0.02% benzalkonium chloride (BAK) eye drops (Xalatan®; Pfizer, NY, USA), travoprost preserved with sofZia® eye drops (Travatan Z®; Alcon, Fort Worth, TX, USA), or preservative-free artificial tears (Refresh Plus®; Allergan, Irvine, CA, USA). Fifteen New Zealand white rabbits were randomised into groups of five (one eye was randomised for treatment) and received once-daily topical application of one of the three treatments for 30 days. Enucleation was performed at the end of the study followed by histologic analysis using mucin stains to identify goblet cells. Goblet cells were quantified and analysed using Student t tests to compare means between groups. Goblet cells per high-power field were 2.21 (±0.40) in the latanoprost with BAK group, 6.02 (±1.20) in the travoprost with sofZia group, and 7.03 (±1.33) in the preservative-free artificial tear group. The number of goblet cells in the latanoprost with BAK group was significantly lower than the other two groups (P=0.0001). There was no statistically significant difference in goblet cell numbers between the travoprost with sofZia and preservative-free artificial tear group (P=0.24). Our study illustrates that, in this animal model, once-daily dosing of latanoprost with 0.02% BAK resulted in goblet cell loss compared with dosing with either travoprost with sofZia or preservative-free artificial tears.
- 1 March 2007
- Published by Springer Nature in Advances in Therapy
- Vol. 24 (2) , 302-309
Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension
This study was undertaken to evaluate the ocular hypotensive efficacy of brimonidine Purite® 0.15% (Alphagan® P 0.15%; Allergan, Inc., Irvine, Calif) given as adjunctive therapy with latanoprost 0.005% (Xalatan®; Pfizer Inc., New York, NY) to patients with open-angle glaucoma or ocular hypertension. In this multicenter, open-label, prospective evaluation, the intraocular pressure (IOP) of the 43 enrolled patients was ≥18 mm Hg after at least 6 wk of latanoprost monotherapy. The primary outcome measure was IOP at peak drug effect (10 am, or approximately 2 h after the morning dose of brimonidine 0.15%). IOP at trough drug effect (8 am, or approximately 12 h after the evening dose of brimonidine) was also measured. Baseline IOP was 21.9 (±2.3) mm Hg. After 1 mo of treatment, additional mean IOP reductions from latanoprost-treated baseline values were 5.8 mm Hg (26%) at peak drug effect (P < .001) and 3.3 mm Hg (15%) at trough (P < .001). At the month 2 visit, additional mean IOP reductions from latanoprost-treated baseline values were 5.1 mm Hg (23%) at peak drug effect (P < .001) and 2.0 mm Hg (9%) at trough (P=.002). Brimonidine Purite 0.15% provided statistically significant additional reductions in IOP from latanoprost-Transmission and reproduction of this material in whole or part without prior written approval are prohibited. treated baseline values. These findings suggest that brimonidine Purite 0.15% is an efficacious adjunctive therapy in patients given latanoprost who require additional lowering of IOP.
- 1 March 2007
- Published by Springer Nature in Advances in Therapy
- Vol. 24 (2) , 302-309
Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension
This study was undertaken to evaluate the ocular hypotensive efficacy of brimonidine Purite® 0.15% (Alphagan® P 0.15%; Allergan, Inc., Irvine, Calif) given as adjunctive therapy with latanoprost 0.005% (Xalatan®; Pfizer Inc., New York, NY) to patients with open-angle glaucoma or ocular hypertension. In this multicenter, open-label, prospective evaluation, the intraocular pressure (IOP) of the 43 enrolled patients was ≥18 mm Hg after at least 6 wk of latanoprost monotherapy. The primary outcome measure was IOP at peak drug effect (10 am, or approximately 2 h after the morning dose of brimonidine 0.15%). IOP at trough drug effect (8 am, or approximately 12 h after the evening dose of brimonidine) was also measured. Baseline IOP was 21.9 (±2.3) mm Hg. After 1 mo of treatment, additional mean IOP reductions from latanoprost-treated baseline values were 5.8 mm Hg (26%) at peak drug effect (P < .001) and 3.3 mm Hg (15%) at trough (P < .001). At the month 2 visit, additional mean IOP reductions from latanoprost-treated baseline values were 5.1 mm Hg (23%) at peak drug effect (P < .001) and 2.0 mm Hg (9%) at trough (P=.002). Brimonidine Purite 0.15% provided statistically significant additional reductions in IOP from latanoprost-Transmission and reproduction of this material in whole or part without prior written approval are prohibited. treated baseline values. These findings suggest that brimonidine Purite 0.15% is an efficacious adjunctive therapy in patients given latanoprost who require additional lowering of IOP.
- 1 January 2007
- Published by Portico in Drugs of Today
- Vol. 43 (2) , 77-83
Travoprost 0.004%/timolol 0.5% fixed combination
Fixed-combination travoprost/timolol solution consists of travoprost 0.004% and timolol 0.5%. Several studies have demonstrated the efficacy and safety of this medication used once daily for the treatment of open-angle glaucoma and ocular hypertension. This fixed combination has been compared to travoprost and timolol used concomitantly, latanoprost and timolol used concomitantly, latanoprost/timolol fixed combination and travoprost and timolol monotherapy. Fixed-combination medicines such as travoprost/timolol offer the potential of maximizing patient adherence by decreasing the burden of using multiple topical agents that lower intraocular pressure, and by potentially decreasing the overall cost to both the patient and the health-care system. We discuss the benefits of fixed-dose medications, report on previous clinical trials and summarize the existing data on the performance of travoprost/timolol.
- 1 January 2007
- Published by Portico in Drugs of Today
- Vol. 43 (2) , 77-83
Travoprost 0.004%/timolol 0.5% fixed combination
Fixed-combination travoprost/timolol solution consists of travoprost 0.004% and timolol 0.5%. Several studies have demonstrated the efficacy and safety of this medication used once daily for the treatment of open-angle glaucoma and ocular hypertension. This fixed combination has been compared to travoprost and timolol used concomitantly, latanoprost and timolol used concomitantly, latanoprost/timolol fixed combination and travoprost and timolol monotherapy. Fixed-combination medicines such as travoprost/timolol offer the potential of maximizing patient adherence by decreasing the burden of using multiple topical agents that lower intraocular pressure, and by potentially decreasing the overall cost to both the patient and the health-care system. We discuss the benefits of fixed-dose medications, report on previous clinical trials and summarize the existing data on the performance of travoprost/timolol.
- 1 November 2006
- Published by BMJ in British Journal of Ophthalmology
- Vol. 90 (11) , 1336-1337
Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
The efficacy of bimatoprost and travoprost in patients with glaucoma and ocular hypertension
- 1 November 2006
- Published by BMJ in British Journal of Ophthalmology
- Vol. 90 (11) , 1336-1337
Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
The efficacy of bimatoprost and travoprost in patients with glaucoma and ocular hypertension
- 21 September 2006
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 22 (11) , 2175-2180
Comparing bimatoprost and travoprost in black Americans
Objective: To compare the intraocular pressurelowering efficacy and safety of topical bimatoprost 0.03% with that of travoprost 0.004% for the reatment of black patients with open-angle glaucoma (OAG) and ocular hypertension (OHT).Research design and methods: Multicenter, prospective, randomized, investigator-masked trial of 94 black patients previously diagnosed with OAG or OHT. All patients completed washout of ocular hypotensive medications before study participation. Patients were assigned to either once-daily bimatoprost 0.03% or once-daily travoprost 0.004% for 3 months.Main outcome measures: The primary outcome measures were mean intraocular pressure (IOP), mean change from baseline IOP, and percentage of patients who reached a target IOP reduction. Secondary measures included ophthalmologic examination and adverse events.Results: Both bimatoprost and travoprost significantly lowered IOP at all study visits ( p < 0.001). Bimatoprost provided mean IOP reductions from baseline that ranged fro...
- 21 September 2006
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 22 (11) , 2175-2180
Comparing bimatoprost and travoprost in black Americans
Objective: To compare the intraocular pressurelowering efficacy and safety of topical bimatoprost 0.03% with that of travoprost 0.004% for the reatment of black patients with open-angle glaucoma (OAG) and ocular hypertension (OHT).Research design and methods: Multicenter, prospective, randomized, investigator-masked trial of 94 black patients previously diagnosed with OAG or OHT. All patients completed washout of ocular hypotensive medications before study participation. Patients were assigned to either once-daily bimatoprost 0.03% or once-daily travoprost 0.004% for 3 months.Main outcome measures: The primary outcome measures were mean intraocular pressure (IOP), mean change from baseline IOP, and percentage of patients who reached a target IOP reduction. Secondary measures included ophthalmologic examination and adverse events.Results: Both bimatoprost and travoprost significantly lowered IOP at all study visits ( p < 0.001). Bimatoprost provided mean IOP reductions from baseline that ranged fro...
- 17 August 2006
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (4) , 497-499
Accuracy and performance of a commercially available Dosing Aid
To evaluate the recently introduced Travatan Dosing Aid (TDA) for its accuracy in recording and dispensing eyedrops. The number of eyedrops dispensed with each lever depression and agreement of total number of drops dispensed with that recorded by the device was evaluated in a controlled setting. The TDA correctly recorded a drop being dispensed 100% of the time with full TDA lever depression for 4 s resulted in unreliable TDA recording. Eyedrops were reliably recorded by the TDA after each full lever depression. However, patients need to be instructed about optimal technique so that evaluation of compliance is not confounded by mechanical factors.
- 17 August 2006
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (4) , 497-499
Accuracy and performance of a commercially available Dosing Aid
To evaluate the recently introduced Travatan Dosing Aid (TDA) for its accuracy in recording and dispensing eyedrops. The number of eyedrops dispensed with each lever depression and agreement of total number of drops dispensed with that recorded by the device was evaluated in a controlled setting. The TDA correctly recorded a drop being dispensed 100% of the time with full TDA lever depression for 4 s resulted in unreliable TDA recording. Eyedrops were reliably recorded by the TDA after each full lever depression. However, patients need to be instructed about optimal technique so that evaluation of compliance is not confounded by mechanical factors.
- 1 May 2006
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 32 (3) , 148-152
Comparison of Initial Treatment Response to Two Enhanced-Viscosity Artificial Tears
To compare the effectiveness of 1.0% carboxymethylcellulose (CMC) (Refresh Liquigel, Allergan, Inc., Irvine, CA) and propylene glycol/polyethylene glycol 400 (PG-HPG) (Systane, Alcon, Fort Worth, TX) in providing relief of dry eye symptoms and signs. To evaluate patient comfort and drop preference, patients were given CMC in one eye and PG-HPG in the other. Five minutes after the initial drop application, patients were questioned on overall preference and comfort, as measured by stickiness, blurring, and soothing. Patients were then randomized to receive CMC or PG-HPG in both eyes for 1 week. Fluorescein staining was evaluated at baseline and week 1. Of patients with a preference, more patients preferred CMC than PG-HPG. Thirty-six percent preferred CMC, and 24% preferred PG-HPG. More (35%) patients found CMC to be more soothing than PG-HPG (22%). After 1 week of treatment, eyes treated with CMC consistently showed less ocular surface staining than did eyes treated with PG-HPG. Mean corneal staining score in the inferior region was significantly lower in the CMC group than in the PG-HPG group (P = 0.008) at week 1. CMC provided a statistically significant decrease in mean corneal inferior staining (P < 0.001), whereas the PG-HPG group (P = 0.185) had no significant change. In the temporal conjunctival region, CMC provided a significantly lower mean staining score than PG-HPG after 1 week of treatment (P = 0.005). Patients found CMC to be more comfortable than PG-HPG. After 1 week of use, CMC provided greater relief of dry eye signs and symptoms than PG-HPG.
- 1 May 2006
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 32 (3) , 148-152
Comparison of Initial Treatment Response to Two Enhanced-Viscosity Artificial Tears
To compare the effectiveness of 1.0% carboxymethylcellulose (CMC) (Refresh Liquigel, Allergan, Inc., Irvine, CA) and propylene glycol/polyethylene glycol 400 (PG-HPG) (Systane, Alcon, Fort Worth, TX) in providing relief of dry eye symptoms and signs. To evaluate patient comfort and drop preference, patients were given CMC in one eye and PG-HPG in the other. Five minutes after the initial drop application, patients were questioned on overall preference and comfort, as measured by stickiness, blurring, and soothing. Patients were then randomized to receive CMC or PG-HPG in both eyes for 1 week. Fluorescein staining was evaluated at baseline and week 1. Of patients with a preference, more patients preferred CMC than PG-HPG. Thirty-six percent preferred CMC, and 24% preferred PG-HPG. More (35%) patients found CMC to be more soothing than PG-HPG (22%). After 1 week of treatment, eyes treated with CMC consistently showed less ocular surface staining than did eyes treated with PG-HPG. Mean corneal staining score in the inferior region was significantly lower in the CMC group than in the PG-HPG group (P = 0.008) at week 1. CMC provided a statistically significant decrease in mean corneal inferior staining (P < 0.001), whereas the PG-HPG group (P = 0.185) had no significant change. In the temporal conjunctival region, CMC provided a significantly lower mean staining score than PG-HPG after 1 week of treatment (P = 0.005). Patients found CMC to be more comfortable than PG-HPG. After 1 week of use, CMC provided greater relief of dry eye signs and symptoms than PG-HPG.